Financial Support Announced for UK's Health Industries - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Financial Support Announced for UK's Health Industries



Innovative business and academic projects from across the UK’s health sector will benefit from a new £93.2 million ($123,909,400 dollars) package of support announced by Universities and Science Minister David Willetts.

The investment includes £25.9 million ($34,434,050 dollars) from Round 3 of the Biomedical Catalyst, through which 29 companies and five universities will receive investment. Projects include clinical trials to repurpose a cancer drug that could be used to treat rheumatoid arthritis and an implant to reduce pain and restore mobility to knee cartilage injuries.

As part of the recent Spending Review, it was announced that there will be additional support for the Catalyst. Academic researchers and universities can continue to apply for additional funding through the Technology Strategy Board and Medical Research Council in Round 4 of the Biomedical Catalyst, which is now open.

A new £38 million ($50,521,000 dollars) National Biologics Manufacturing Centre will be based in Darlington. The centre, being funded through investment announced as part of the life sciences strategy, will be a national base for the manufacturing of biological medicines such as antibodies and vaccines.

A further £29.3 million ($38,954,350 dollars) of investment in healthcare innovation has been announced through three Technology Strategy Board-led funding competitions. These will support businesses in areas such as stratified medicine and regenerative medicin.

Source: UK Department for Business Innovation and Skills

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here